SEC Filing Summary: ChromaDex Corporation (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on December 16, 2016, reporting an event that occurred on December 13, 2016. The filing addresses the entry into a Material Definitive Agreement regarding corporate governance and liability protection.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is non-financial in nature and contains no financial statements or performance data.
Material Changes
On December 13, 2016, the Company entered into new Indemnity Agreements with each of its existing directors and executive officers. These agreements supersede any previously existing indemnity agreements. The new agreements provide that the Company may be required to indemnify covered individuals for claims arising from their capacity as directors, officers, employees, or agents. These rights are in addition to protections under the Company's Certificate of Incorporation, Bylaws, and Delaware law.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. The primary risk disclosed relates to the Company's potential financial obligation to indemnify directors and officers against claims, though the specific terms are detailed in the attached Exhibit 10.1.
Investor Verification Checklist
- Verify the full text of the Indemnity Agreement attached as Exhibit 10.1 to understand specific coverage limits and exclusions.
- Confirm the Company's legal name is ChromaDex Corporation, as the input metadata referenced "Niagen Bioscience, Inc."
- Review the Company's Amended and Restated Certificate of Incorporation and Bylaws to understand the baseline indemnification rights prior to this agreement.